You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 39 Interim analysis of ovarian cancer by the us national cancer moonshot’s tri-federal (DOD/NCI/VA) applied proteogenomic organizational learning and outcomes (APOLLO) research network

Article Text

Article menu

Download PDFPDF

Plenary sessions
Plenary 6
IGCS19-0345
39 Interim analysis of ovarian cancer by the us national cancer moonshot’s tri-federal (DOD/NCI/VA) applied proteogenomic organizational learning and outcomes (APOLLO) research network
Free
  1. GL Maxwell1,2,
  2. NW Bateman2,3,
  3. AR Soltis4,
  4. G Wang3,
  5. CL Dalgard4,
  6. EF Petricoin5,
  7. CM Tarney6,
  8. C Rojas6,
  9. L Havrilesky7,
  10. DE Cohn8,
  11. JM Wells9,
  12. H Hu10,
  13. CA Hamilton1,2,
  14. CD Shriver11,
  15. M Wilkerson4,
  16. Y Casablanca2,12,
  17. K Darcy2,3 and
  18. TP Conrads1,2
  1. 1Inova Women’s Hospital- the Inova Women’s Service Line- and the Inova Schar Cancer Center, The Women’s Health Integrated Research Center and the Department of Obstetrics and Gynecology, Falls Church, USA
  2. 2The John P Murtha Cancer Center- the Uniformed Services University of the Health Sciences- and Walter Reed National Military Medical Center, Gynecologic Cancer Center of Excellence, Bethesda- MD, USA
  3. 3The Henry M. Jackson Foundation for the Advancement of Military Medicine, Gynecologic Cancer Center of Excellence, Bethesda- MD, USA
  4. 4Uniformed Services University of the Health Sciences, The American Genome Center, Bethesda- MD, USA
  5. 5George Mason University, Applied Center for Proteogenomics, Manassas- VA, USA
  6. 6Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Division of Gynecologic Oncology, Bethesda- MD, USA
  7. 7Duke University Medical Center, Division of Gynecologic Oncology, Durham- NC, USA
  8. 8The James Comprehesive Cancer Center and Ohio State University, Division of Gynecologic Oncology, Columbus- OH, USA
  9. 9Walter Reed National Military Medical Center, Department of Pathology, Bethesda- MD, USA
  10. 10Chan Soon-Shiong Institute of Molecular Medicine, Department of Bioinformatics, Windber- PA, USA
  11. 11Uniformed Services University of the Health Sciences, John P Murtha Cancer Center, Bethesda- MD, USA
  12. 12Walter Reed National Military Medical Center, Division of Gynecologic Oncology, Bethesda- MD, USA

Abstract

Objectives Although studies including TCGA have selected for pure tumors to enhance detection of cancer-related biomarkers, many impure tumors are associated with poor prognosis raising concerns over historical selection bias. Enrichment techniques to prep tumor micro-compartments was aligned with comprehensive proteogenomic analysis in an advanced stage high grade serous ovarian cancer (HGSOC) patient cohort to detect novel, clinically-relevant alterations.

Methods 87 fresh-frozen tumor specimens were selected from a cohort of over 630 patients to reflect a continuum of tumor purity balanced by progression and disease distribution. A whole tumor (WT) specimen and one enriched for tumor epithelium was prepared for each case using laser microdissection (LMD). Specimens were analyzed by whole genome sequencing (WGS), mRNA-seq, quantitative global/phosphoproteomics, and reverse phase protein array.

Results LMD enrichment increased median tumor purity estimated by WGS from 56% in WT to 79% (P<4e-11, MWW U test) and significantly enhanced identification of somatic single nucleotide variants (SNVs) (27%, P<3e-7) and short indels (16%, P<4e-4). Following LMD, 83% of cases characterized as mesenchymal expression subtype (C4) in WT samples were reclassified to other molecular subtypes (P<0.001). LMD tumors with an immune expression subtype (C1) had improved progression-free survival (PFS) compared with other molecular subtypes (p=0.009). Differential proteomic analyses focused on signaling alterations correlating with altered PFS, homologous recombination deficiency and immune signaling.

Abstract 39 Figure 1
Abstract 39 Figure 1

Conclusions These data demonstrate feasibility of cohort-level proteogenomic characterization of the tumor microenvironment and establishes a non-restrictive paradigm for patient inclusion and specimen prep in support of the prospective mission-scale analyses associated with APOLLO.

https://doi.org/10.1136/ijgc-2019-IGCS.39

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.